Skip to main content

Peer Review reports

From: Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran

Original Submission
31 May 2023 Submitted Original manuscript
13 Nov 2023 Reviewed Reviewer Report
21 Nov 2023 Reviewed Reviewer Report - Mohammadreza Amirsadri
2 Jan 2024 Author responded Author comments - Khosro Keshavarz
Resubmission - Version 2
2 Jan 2024 Submitted Manuscript version 2
23 Jan 2024 Author responded Author comments - Khosro Keshavarz
Resubmission - Version 3
23 Jan 2024 Submitted Manuscript version 3
23 Jan 2024 Author responded Author comments - Khosro Keshavarz
Resubmission - Version 4
23 Jan 2024 Submitted Manuscript version 4
24 Jan 2024 Reviewed Reviewer Report - Mohammadreza Amirsadri
2 Feb 2024 Reviewed Reviewer Report
6 Feb 2024 Author responded Author comments - Khosro Keshavarz
Resubmission - Version 5
6 Feb 2024 Submitted Manuscript version 5
10 Feb 2024 Reviewed Reviewer Report - Mohammadreza Amirsadri
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
12 Feb 2024 Editorially accepted
20 Feb 2024 Article published 10.1186/s12894-024-01431-w

You can find further information about peer review here.

Back to article page